Article
Endocrinology & Metabolism
Keiu Heinla, Eero Vasar, Ingrid Reppo, Tuuli Sedman, Vallo Volke
Summary: The study investigates the effect of GLP-1RAs on growth hormone (GH) secretion. Two separate clinical trials were conducted to examine the impact of short-acting and long-acting GLP-1RAs on GH levels. The findings suggest that GLP-1RAs may increase GH secretion, indicating a potential novel mechanism for regulating GH.
Article
Cardiac & Cardiovascular Systems
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini, Katherine Esposito
Summary: Glucagon-like peptide-1 receptor agonists have significant benefits on cardiovascular and renal outcomes in patients with type 2 diabetes, including reducing major cardiovascular events, hospitalization for heart failure, all-cause mortality, and the incidence of macroalbuminuria.
CARDIOVASCULAR DIABETOLOGY
(2021)
Review
Pharmacology & Pharmacy
Athanasia K. Papazafiropoulou, Andreas Melidonis, Stavros Antonopoulos
Summary: In recent years, research has shown that GLP-1 receptor agonists and SGLT2 inhibitors not only improve glycemic control in diabetic patients, but also have positive effects on cardiovascular risk factors and weight. These drugs may also have benefits for non-diabetic patients.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Pharmacology & Pharmacy
Guoxiang Tong, Tianhao Peng, Ya Chen, Lijuan Sha, Huikang Dai, Yidong Xiang, Zhiqi Zou, Heli He, Sha Wang
Summary: Colorectal cancer is a common and deadly disease. Single drug therapy has limitations, while combination targeted drug therapy shows promise. This study focuses on the effects of the GLP-1 receptor agonist liraglutide on CRC cells and the PI3K/Akt/mTOR signaling pathway, aiming to find alternative treatments for CRC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Reema Mody, Maria Yu, Bal Nepal, Manige Konig, Michael Grabner
Summary: The study found that patients initiating dulaglutide showed higher rates of adherence and persistence with their treatment compared to those initiating semaglutide or exenatide BCise at the 6-month follow-up.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Xin Zhao, Minghe Wang, Zhitong Wen, Zhihong Lu, Lijuan Cui, Chao Fu, Huan Xue, Yunfeng Liu, Yi Zhang
Summary: GLP-1 receptor agonists have been widely used in the treatment of type 2 diabetes due to their beneficial effects such as weight loss and protection of islet cells. Studies have shown that they have multiple biological effects on various tissues and organs, leading to potential applications in neuroprotection, cardiovascular protection, and metabolic regulation. The relationship between GLP-1RAs and tumorigenesis in patients with type 2 diabetes is also a subject of growing interest.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Rasmus Stenlid, Sara Y. Cerenius, Quan Wen, Banu Kucukemre Aydin, Hannes Manell, Azazul Chowdhury, Hjalti Kristinsson, Iris Ciba, Erik S. Gjessing, Katharina Moerwald, Julian Gomahr, Verena Heu, Daniel Weghuber, Anders Forslund, Peter Bergsten
Summary: Weekly injections of 2 mg exenatide extended release maintain endogenous total GLP-1 levels and lower circulating DPP-4 levels. This provides supportive evidence for the use of exenatide in the treatment of pediatric obesity.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal
Summary: Glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide have expanded the population of individuals reaching HbA1c and weight targets, showing potential therapeutic benefits. However, further research is needed to determine whether this will lead to improved cardiovascular outcomes and impact treatment guidelines.
DIABETES OBESITY & METABOLISM
(2022)
Article
Gastroenterology & Hepatology
Judith van Dalem, Johanna H. M. Driessen, Andrea M. Burden, Coen D. A. Stehouwer, Olaf H. Klungel, Frank de Vries, Martijn C. G. J. Brouwers
Summary: The study found that patients prescribed TZDs had a lower risk of NAFLD, while there was no significant difference in NAFLD risk between GLP-1 receptor agonist use and insulin use.
Review
Endocrinology & Metabolism
Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor
Summary: This communication presents a modern classification of GLP1RAs based on indication, route, and frequency, aiming to support individualized treatment choices. It includes recently developed GLP1RAs and those in advanced clinical studies, aiming to simplify and clarify complex information in line with trends in pharmacology and metabolic medicine.
Article
Pharmacology & Pharmacy
Qiang Wu, Song Chen, Hanchen Zhu, Na Xu, Qianhua Yang, Wenbing Yao, Xiangdong Gao
Summary: This study focused on the characteristics and optimization of GLP-1 receptor endocytosis, using various methods to analyze the effects and screen potential agonists for treatment of type 2 diabetes mellitus. The results showed that endocytosis of GLP-1 receptor-mediated elimination was clathrin-dependent, and agonists biased towards the G protein pathway had less endocytosis. The identified analogue M4 showed prolonged hypoglycaemic activities and a long half-life, making it a potential lead compound for type 2 diabetes mellitus treatment.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Chemistry, Applied
Ivan Guryanov, Andrea Orlandin, Ivan De Paola, Angelo Viola, Barbara Biondi, Denis Badocco, Fernando Formaggio, Antonio Ricci, Walter Cabri
Summary: Peptides as APIs are gaining interest, requiring efficient preparation strategies. This study presents a method for the synthesis of GLP-1 receptor agonist lipopeptides using pseudoproline-assisted convergent synthesis, effectively preventing peptide aggregation and improving yield. A novel approach involving copper(II) lysinate intermediates is also developed for the synthesis of lipidated side chains, which is suitable for industrial preparation of similar branched peptides.
ORGANIC PROCESS RESEARCH & DEVELOPMENT
(2021)
Article
Gastroenterology & Hepatology
Dinghui Liu, Juan Pang, Weijuan Shao, Jianqiu Gu, Yong Zeng, Housheng Hansen He, Wenhua Ling, Xiaoxian Qian, Tianru Jin
Summary: This study suggests that liraglutide-stimulated hepatic Fgf21 expression may require GLP-1R to be expressed in extrahepatic organs and reveals that hepatic FGF21 is necessary for liraglutide to lower body weight and improve hepatic lipid homeostasis. These findings advance our understanding of the mechanisms behind the function of GLP-1-based drugs in NAFLD.
Review
Endocrinology & Metabolism
Rashmi Shetty, Fathima Thashreefa Basheer, Pooja Gopal Poojari, Girish Thunga, Viji Pulikkel Chandran, Leelavathi D. Acharya
Summary: GLP-1 agonists are associated with a significant number of adverse drug reactions (ADRs), with gastrointestinal disorders being the most frequently reported reaction, particularly pancreatitis. Liraglutide and exenatide are the two drugs most commonly associated with ADRs.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Article
Biochemistry & Molecular Biology
Hisayuki Katsuyama, Mariko Hakoshima, Shohei Umeyama, Sakura Iida, Hiroki Adachi, Hidekatsu Yanai
Summary: This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum HDL-C, TG, and non-HDL-C.